Skip to main content
. 2018 Feb 23;13(2):e0193380. doi: 10.1371/journal.pone.0193380

Fig 5. AZD9977, eplerenone and co-treatment with enalapril reduce albuminuria in diabetic kidney disease.

Fig 5

db/db mice uni-nephrectomised at 8 weeks of age were treated from age 18w to age 22w with 100 mg kg-1 d-1 AZD9977 or 100 mg kg-1 d-1 eplerenone alone or in combination with enalapril. (a) Total urine albumine secreted over 24 hours was assessed. (b) Glomerular ECM scores were quantitated as % of glomerular tuft staining. (c) Histological sections stained with PAS. Representative photomicrographs of glomeruli from lean control mice (L), diabetic db/db mice without treatment at 18 weeks of age (w18) or at 22 weeks of age (w22) and diabetic db/db mice treated with AZD9977 (AZ), eplerenone (EP), enalapril (EN), combination of AZD9977 and enalapril (EN+AZ) and eplerenone and enalapril (EN+EP). The scale bar corresponds to 50 μm original size. Average +/- SEM; n = 7–9; *p<0.05 compared to vehicle at 22 weeks of age. #p<0.05 compared to enalapril treatment.